Medipost has announced that its allogeneic human umbilical cord blood-derived mesenchymal stem cell product for knee osteoarthritis was featured in the peer-reviewed Orthopaedic Journal of Sports Medicine.
The Seoul, Korea–headquartered company specializes in allogeneic umbilical cord blood-derived mesenchymal stem cells for various therapeutic applications.
Medipost’s Phase 3 study found that 97% of recipients of its Cartistem cellular therapeutic agent showed significant improvement in cartilage restoration after 48 weeks.
Participants in the study underwent a five-year observational follow-up.More than a decade of Cartistem history
South Korean regulatory authorities approved Cartistem in January 2012, making it one of the world’s first companies to obtain approval for cell therapy.
Medipost is optimistic about the potential to expand the use of Cartistem, given the rising rates of knee osteoarthritis. “People are gett…